Literature DB >> 19339071

Endo-rectal balloon cavity dosimetry in a phantom: performance under IMRT and helical tomotherapy beams.

Nicholas Hardcastle1, Peter E Metcalfe, Anatoly B Rosenfeld, Wolfgang A Tomé.   

Abstract

BACKGROUND AND
PURPOSE: The use of endo-rectal balloons as immobilisation devices in external beam radiotherapy for prostate cancer has led to improved target position reproducibility and a decrease in rectal toxicity. The air cavity created by an endo-rectal balloon in photon radiotherapy perturbs the dose distribution. In this study, the effect of the balloon cavity on the dose distribution and the accuracy to which two treatment planning systems calculate the dose distribution were investigated.
MATERIALS AND METHODS: Single beams as well as 3D conformal, conventional IMRT and helical tomotherapy treatment plans were investigated using a specifically constructed phantom. Radiochromic film was used to measure the cavity wall doses and cavity wall DVHs.
RESULTS: For a 70 Gy prescription dose both the Pinnacle and TomoTherapy TPSs over-predicted the anterior cavity wall dose by 1.43 Gy, 3.92 Gy and 2.67 Gy for 3D conformal, conventional IMRT and helical tomotherapy, respectively. The posterior cavity wall dose was under-predicted by 2.62 Gy, 2.01 Gy and 4.79 Gy for 3D conformal, conventional IMRT and helical tomotherapy, respectively. An over-prediction by the Pinnacle RTPS of the V50, V60, V65 and V70 values for the cavity wall DVH was measured for the 3D conformal and conventional IMRT cases. These reductions may lead to a less than expected rectal toxicity. The TomoTherapy RTPS under-predicted the V50, V60, V65 and V70 values which may lead to higher rectal toxicity than predicted.
CONCLUSION: Calculation of dose around an air cavity created by an endo-rectal balloon provides a challenge for radiotherapy planning systems. Various electronic disequilibrium situations exist due to the cavity, which can lead to a lower anterior rectal wall and higher posterior rectal wall dose than that calculated by planning systems. This has consequences for comparisons of dose volume constraints between different modalities.

Entities:  

Mesh:

Year:  2009        PMID: 19339071      PMCID: PMC2700219          DOI: 10.1016/j.radonc.2009.03.004

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  52 in total

1.  A simple analytic derivation suggests that prostate cancer alpha/beta ratio is low.

Authors:  C R King; J F Fowler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-09-01       Impact factor: 7.038

2.  Predictors for rectal and intestinal acute toxicities during prostate cancer high-dose 3D-CRT: results of a prospective multicenter study.

Authors:  Vittorio Vavassori; Claudio Fiorino; Tiziana Rancati; Alessandro Magli; Gianni Fellin; Michela Baccolini; Carla Bianchi; Emanuela Cagna; Flora A Mauro; Angelo F Monti; Fernando Munoz; Michele Stasi; Paola Franzone; Riccardo Valdagni
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-01-22       Impact factor: 7.038

3.  Is alpha/beta for prostate tumors really low?

Authors:  J Fowler; R Chappell; M Ritter
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-07-15       Impact factor: 7.038

4.  The influence of a rectal balloon tube as internal immobilization device on variations of volumes and dose-volume histograms during treatment course of conformal radiotherapy for prostate cancer.

Authors:  Stefan Wachter; Natascha Gerstner; Daniela Dorner; Gregor Goldner; Adriana Colotto; Andre Wambersie; Richard Pötter
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-01-01       Impact factor: 7.038

5.  Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue.

Authors:  David J Brenner; Alvaro A Martinez; Gregory K Edmundson; Christina Mitchell; Howard D Thames; Elwood P Armour
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-01-01       Impact factor: 7.038

6.  Short-course intensity-modulated radiotherapy (70 GY at 2.5 GY per fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life.

Authors:  P A Kupelian; C A Reddy; E A Klein; T R Willoughby
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-11-15       Impact factor: 7.038

7.  Intensity-modulated radiation therapy (IMRT) for prostate cancer with the use of a rectal balloon for prostate immobilization: acute toxicity and dose-volume analysis.

Authors:  B S Teh; W Y Mai; B M Uhl; M E Augspurger; W H Grant; H H Lu; S Y Woo; L S Carpenter; J K Chiu; E B Butler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-03-01       Impact factor: 7.038

8.  Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: analysis of a large group of patients pooled from three institutions.

Authors:  Claudio Fiorino; Cesare Cozzarini; Vittorio Vavassori; Giuseppe Sanguineti; Carla Bianchi; Giovanni Mauro Cattaneo; Franca Foppiano; Alessandro Magli; Anna Piazzolla
Journal:  Radiother Oncol       Date:  2002-07       Impact factor: 6.280

9.  Underdosage of the upper-airway mucosa for small fields as used in intensity-modulated radiation therapy: a comparison between radiochromic film measurements, Monte Carlo simulations, and collapsed cone convolution calculations.

Authors:  C Martens; N Reynaert; C De Wagter; P Nilsson; M Coghe; H Palmans; H Thierens; W De Neve
Journal:  Med Phys       Date:  2002-07       Impact factor: 4.071

10.  Prostate immobilization using a rectal balloon.

Authors:  John E McGary; Bin S Teh; E Brian Butler; Walter Grant
Journal:  J Appl Clin Med Phys       Date:  2002       Impact factor: 2.102

View more
  7 in total

1.  Quality assurance of an image guided intracranial stereotactic positioning system for radiosurgery treatment with helical tomotherapy.

Authors:  Emilie T Soisson; Nick Hardcastle; Wolfgang A Tomé
Journal:  J Neurooncol       Date:  2010-05-27       Impact factor: 4.130

2.  In vivo real-time rectal wall dosimetry for prostate radiotherapy.

Authors:  Nicholas Hardcastle; Dean L Cutajar; Peter E Metcalfe; Michael L F Lerch; Vladimir L Perevertaylo; Wolfgang A Tomé; Anatoly B Rosenfeld
Journal:  Phys Med Biol       Date:  2010-07-07       Impact factor: 3.609

3.  Comparing photon and proton-based hypofractioned SBRT for prostate cancer accounting for robustness and realistic treatment deliverability.

Authors:  Lee C Goddard; N Patrik Brodin; William R Bodner; Madhur K Garg; Wolfgang A Tomé
Journal:  Br J Radiol       Date:  2018-03-02       Impact factor: 3.039

4.  In-phantom dose verification of prostate IMRT and VMAT deliveries using plastic scintillation detectors.

Authors:  David Klein; Tina Marie Briere; Rajat Kudchadker; Louis Archambault; Luc Beaulieu; Andrew Lee; Sam Beddar
Journal:  Radiat Meas       Date:  2012-08-24       Impact factor: 1.898

5.  Endorectal balloon (ERB) in helical tomotherapy (HT) for localized prostate cancer: a case report of dosimetric analysis.

Authors:  Seung-Gu Yeo; Kwang Hwan Cho
Journal:  Transl Cancer Res       Date:  2021-09       Impact factor: 1.241

6.  Dataset for predicting single-spot proton ranges in proton therapy of prostate cancer.

Authors:  Hugo Freitas; Paulo Magalhaes Martins; Thomas Tessonnier; Benjamin Ackermann; Stephan Brons; Joao Seco
Journal:  Sci Data       Date:  2021-09-29       Impact factor: 6.444

7.  Towards real-time PGS range monitoring in proton therapy of prostate cancer.

Authors:  Paulo Magalhaes Martins; Hugo Freitas; Thomas Tessonnier; Benjamin Ackermann; Stephan Brons; Joao Seco
Journal:  Sci Rep       Date:  2021-07-28       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.